Full-Time
Tech-driven personalized supplements via DTC subscription
$115k - $135k/yr
H1B Sponsorship Available
San Francisco, CA, USA
In Person
Travel up to 25% domestically and internationally.
Bachelor's, Master's
| , |
See people who can refer or advise you
Multiply Labs creates personalized vitamins and supplements using a proprietary tech platform that analyzes factors like age, lifestyle, and health goals to design a customized regimen. Products are sold directly to consumers through multiplylabs.com, typically on a subscription, enabling ongoing, data-informed adjustments. The approach combines science-based customization with a direct-to-consumer model to deliver precise nutrition for fitness enthusiasts and people with specific dietary needs, aiming for steady growth and better health outcomes.
Company Size
51-200
Company Stage
Series A
Total Funding
$23M
Headquarters
San Francisco, California
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Work from home option
Multiply Labs - Funding & investors. Last updated: April 6, 2026 Multiply Labs' funding rounds. Multiply Labs has raised a total of $41.3M over 7 funding rounds: 3 Seed and 4 Early-Stage round s. Multiply Labs' largest funding round so far was a Series A round for $***** in Apr 2021. Here is the list of all funding rounds of Multiply Labs: | Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors | | Apr 21, 2023 | 2041367 | Series A | 3319109 | 9135293 | 3099539 | 4086360 | | Apr 14, 2021 | 2657263 | Series A | 5925816 | 4466755 | 6608485 | Lux Capital & 3 more | | Oct 27, 2018 | 9572761 | Series A | 4644887 | 9212511 | 8077938 | 2014680 | | May 11, 2017 | 4797781 | Series A | 3875885 | 9861974 | 3348546 | Graph Ventures & 5 more | | 2016 | 3338 | Seed | 8966 | 6394 | MIT Sandbox Innovation Fund Program | 1984 | | Aug 22, 2016 | 6270815 | 275706 | 1251781 | 3745093 | 8161543 | 4582795 | | Aug 20, 2016 | 6353672 | 624806 | 7882936 | 5171611 | 9475670 | 8336843 | Multiply Labs' investors. Multiply Labs has total 24 investor s, 24 are institutional investors including Y Combinator and 23 others. Here is the list of institutional investors of Multiply Labs: * Lux Capital, located in Menlo Park (United States), made their first investment in Multiply Labs on Apr 14, 2021 in its Series A round. * Graph Ventures, located in San Francisco (United States), made their first investment in Multiply Labs on May 11, 2017 in its Series A round. * MIT Sandbox Innovation Fund Program, located in Cambridge (United States), made their first investment in Multiply Labs on 2016 in its Seed round. Are you a Founder? FAQs about Multiply Labs' funding and investors. Multiply Labs has raised a total of $41.3M over 7 rounds. Multiply Labs' largest funding round was a Series A round held on Apr 14, 2021 for $*****. * 4 Early-Stage rounds * 3 Seed rounds Multiply Labs has a total of 24 investors, all of them are Institutional investors. Explore latest companies that raised funding recently * Budderfly - Shelton based, raised a funding of $100M in Conventional Debt round held on Jun 23, 2025. * Vizsla Silver - Vancouver based, raised a funding of $100M in Post IPO round held on Jun 23, 2025. * PhysicsX - London based, raised a funding of $135M in Series B round held on Jun 23, 2025. * Techarena - raised a funding of $1.24M in Seed round held on Jun 23, 2025. * Tattle - New York City based, raised a funding of $1.5M in Venture Debt round held on Jun 23, 2025.
Multiply Labs has announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration will focus on end-to-end robotic automation of industry-standard instruments using Multiply Labs' biomanufacturing platform. The San Francisco-based robotics company develops autonomous manufacturing technology for advanced therapies. Its newest systems use four robotic arms operating in parallel to run cell therapy manufacturing instruments, aiming to maximise output whilst minimising process modifications. "Cell therapies are among the most promising, yet complex medicines being developed today," said Fred Parietti, CEO of Multiply Labs. "Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale." The collaboration seeks to enable scalable, high-throughput manufacturing whilst maintaining quality and regulatory standards for clinical and commercial use.
Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).
Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function